Clinical research progress of lusutrombopag for the treatment of thrombocytopenia in chronic liver disease
10.3760/cma.j.cn501113-20230830-00080
- VernacularTitle:芦曲泊帕治疗慢性肝病血小板减少症的临床研究进展
- Author:
Zheng XU
1
;
Jiyuan ZHANG
;
Fusheng WANG
Author Information
1. 解放军总医院第五医学中心感染病医学部，北京 100039
- Keywords:
Thrombocytopenia;
Liver disease;
Treatment;
Thrombopoietin receptor agonist;
Lusutrombopag
- From:
Chinese Journal of Hepatology
2024;32(10):943-947
- CountryChina
- Language:Chinese
-
Abstract:
Thrombocytopenia is one of the common complications with the hematologic system in patients with chronic liver disease, which often causes poor quality of life and high risk of bleeding, thereby affecting their diagnosis, treatment, and prognosis. Platelet transfusion can improve the patient's declining platelet count to a certain extent, but it has problems such as high price and being easy to cause immune rejection. Thrombopoietin (TPO), as an important cytokine that affects platelet production, can bind to TPO receptors and activate megakaryocytes to produce platelets. Lusutrombopag is a newly developed small-molecule TPO receptor agonist that can induce bone marrow progenitor cells to differentiate into megakaryocytes and increase platelet production, posing characteristics of oral convenience, safety and effectiveness; thus, it has been used in many countries and regions for the treatment of patients with chronic liver diseases concurrent with thrombocytopenia. Herein, the pharmacological features and clinical research are reviewed.
